Glenmark Company Profile
✉ Email this page to a colleague
What is the competitive landscape for GLENMARK, and what generic alternatives to GLENMARK drugs are available?
GLENMARK has one hundred and ninety approved drugs.
There are fourteen US patents protecting GLENMARK drugs. There are eleven tentative approvals on GLENMARK drugs.
There are eighty patent family members on GLENMARK drugs in thirty-two countries and five hundred and two supplementary protection certificates in eighteen countries.
Summary for Glenmark
| International Patents: | 80 |
| US Patents: | 14 |
| Tradenames: | 149 |
| Ingredients: | 139 |
| NDAs: | 190 |
| Patent Litigation for Glenmark: | See patent lawsuits for Glenmark |
Drugs and US Patents for Glenmark
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glenmark Pharms Ltd | FLUCINOLONE ACETONIDE | fluocinolone acetonide | OIL;TOPICAL | 210556-001 | Oct 25, 2018 | AT | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Glenmark Pharms Ltd | APREMILAST | apremilast | TABLET;ORAL | 211674-003 | Oct 16, 2023 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Glenmark Pharms Ltd | RALOXIFENE HYDROCHLORIDE | raloxifene hydrochloride | TABLET;ORAL | 204491-001 | Mar 22, 2016 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for GLENMARK drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
International Patents for Glenmark Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Malaysia | 176808 | ⤷ Try a Trial |
| Australia | 2019224850 | ⤷ Try a Trial |
| Hungary | E052939 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Glenmark Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0888289 | SPC/GB09/007 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: LACOSAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE FORMS; REGISTERED: UK EU/1/08/470/001 20080829; UK EU/1/08/470/002 20080829; UK EU/1/08/470/003 20080829; UK EU/1/08/470/004 20080829; UK EU/1/08/470/005 20080829; UK EU/1/08/470/006 20080829; UK EU/1/08/470/014 20080829; UK EU/1/08/470/015 20080829; UK EU/1/08/470/016 20080829; UK EU/1/08/470/007 20080829; UK EU/1/08/470/008 20080829; UK EU/1/08/470/009 20080829; UK EU/1/08/470/010 20080829; UK EU/1/08/470/012 20080829; UK EU/1/08/470/013 20080829 |
| 0480717 | 19/1999 | Austria | ⤷ Try a Trial | PRODUCT NAME: MONTELUKAST ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE MONTELUKASTNATRIUM; NAT. REGISTRATION NO/DATE: 1-22765 UND 1-22766 19981030; FIRST REGISTRATION: FI 12766 UND 12767 19970825 |
| 2782584 | LUC00245 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (Y COMPRIS SOUS FORME HEMIHYDRATEE), ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210701 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
